

# TABLE OF CONTENTS

1. Overview
2. Briefing Document by Hugo Gallo-Torres, M.D., Ph.D.
3. Sample of a Written Request for Proton-Pump Inhibitors Used to Treat Gastroesophageal Reflux Disease
4. Usage data for proton-pump inhibitors in pediatrics
5. Letter from George D. Ferry, M.D.
6. References

## List of References

### Gastroesophageal reflux disease in pediatrics

1. Faubion, WA, Zein, NN. Gastroesophageal reflux in infants and children. *Mayo Clinic Proc.* 1998; 73:166-173.
2. Orenstein, SR. Management of supraesophageal complications of gastroesophageal reflux disease in infants and children. *The American Journal of Medicine.* 2000; 108(4A):139S-143S.
3. Vandenas, Y, Sacre, J-Smits, L. Continuous 24-hour esophageal pH monitoring in 285 asymptomatic infants 0-15 months old. *Journal of Pediatric Gastroenterology and Nutrition.* 1987; 6(2):220-224.
4. Thach, BT. Reflux associated apnea in infants: Evidence for a laryngeal chemoreflex. *The American Journal of Medicine.* 1997; 103(5A): 120S-124S.

### Gastroesophageal reflux in neonates

5. Jadcherla, SR. Gastroesophageal reflux in the neonate. *Clinics in Perinatology.* 2002; 29(1):135-158.
6. Newell, SJ, Booth, IW, Morgan, MEI, *et.al.* Gastro-oesophageal reflux in preterm infants. *Archives of Disease in Childhood,* 1989;64:780-786.
7. Marino, AJ, Assing, E, Carbone, MT, *et.al.* The incidence of gastroesophageal reflux in preterm infants. *Journal of Perinatology.* 1995; 15(5):369-371.
8. Kimball, AL, Carlton, DP. Gastroesophageal reflux medications in the treatment of apnea in premature infants. *The Journal of Pediatrics.* 2001;138(3): 355-360.
9. Page, M, Jeffery, H. The role of gastro-oesophageal reflux in the aetiology of SIDS. *Early Human Development.* 2000; 59:127-149.
10. Barrington, KJ, Tan, K, Rich, W. Apnea at discharge and gastro-oesophageal reflux in the preterm infant. *Journal of Perinatology.* 2002; 22:8-11.

### Respiratory and supraesophageal manifestations of gastroesophageal reflux

11. Menon, AP, Schefft, GL, Thach, BT. Apnea associated with regurgitation in infants. *The Journal of Pediatrics.* 1985; 106(4):625-629.
12. Orlando, R. Mechanisms of reflux-induced epithelial injuries in the esophagus. *The American Journal of Medicine.* 2000; 108(4A):104S-107S.

13. Richter, JE. Gastroesophageal reflux disease and asthma: The two are directly related. *The American Journal of Medicine*. 2000; 108(4A):153S-158S.
14. Holloway, RH. Esophageal body motor response to reflux events: Secondary peristalsis. *The American Journal of Medicine*. 2000; 108(4A):20S-26S.
15. Peter, CS, Sprodowski, N, Bohnhorst, B, *et.al*. Gastroesophageal reflux and apnea of prematurity: No temporal relationship. *Pediatrics*. 2002; 109(1): 8-11.

#### Ethics

16. *FDA Ethics Working Group Consensus Statement on the Pediatric Advisory Subcommittee's November 15, 1999 Meeting*. ([www.fda.gov/cder/pediatric/ethics-statement.htm](http://www.fda.gov/cder/pediatric/ethics-statement.htm)) (accessed 4/29/02).
17. *FDA Pediatric Ethics Working Group Consensus Statement on Pediatric Advisory Subcommittee's September 11, 2000 Meeting*. ([www.fda.gov/cder/pediatric/ethics-statement.htm](http://www.fda.gov/cder/pediatric/ethics-statement.htm)). (accessed 4/29/02).

#### Special study designs: Randomized-withdrawal trials

18. Temple, RJ. Special study designs: Early escape, enrichment, studies in non-responders. *Commun. Statist. Theory Meth*. 1994; 23(2):499-531.

#### Choice of control group in clinical studies

19. *Guidance For Industry: E 10 Choice of Control Group and Related Issues in Clinical Trials*. Food and Drug Administration. May 2001.
20. Temple, R, Ellenberg, S. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues. *Annals of Internal Medicine*. 2000; 133(6):455-463.
21. Ellenberg, S, Temple, R. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: Practical issues and specific cases. *Annals of Internal Medicine*. 2000; 133(6): 464-475.
22. Temple, RJ. When are clinical trials of a given agent vs. placebo no longer appropriate or feasible? *Controlled Clinical Trials*. 1997; 18:613-620

#### Pharmacology of proton-pump inhibitors

23. James, LP. Pharmacology for the gastrointestinal tract. *Clinics in Perinatology*. 2002; 29(1):115-133.

24. Wolfe, MM, Sachs, G. Acid suppression: Optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. *Gastroenterology*. 2000; 118:S9-S31.
25. Richardson, *et.al*. Proton pump inhibitors in GI disorders. *Drugs*. 1998; 56(3):308-334.
26. Sachs, G, Shin, JM, Briving, C, *et.al*. The pharmacology of the gastric acid pump: The H<sup>+</sup>, K<sup>+</sup> ATPase. *Annual Review of Pharmacology and Toxicology*. 1995; 33:277-305.

